Search

Your search keyword '"Vallot, Frédéric"' showing total 47 results
Start Over Author "Vallot, Frédéric"
47 results on '"Vallot, Frédéric"'

2. Immunological sub-phenotypes and response to Convalescent Plasma in COVID-19 induced ARDS: a secondary analysis of the CONFIDENT trial.

Author

Misset, Benoit, primary, Diep, Anh Nguyet, additional, Bertrand, Axelle, additional, Piagnerelli, Michael, additional, Hoste, Eric, additional, Michaux, Isabelle, additional, De Waele, Elisabeth, additional, Dumoulin, Alexander, additional, Jorens, Philippe G, additional, Hauwaert, Emmanuel van der, additional, Vallot, Frédéric, additional, Swinnen, Walter, additional, De Schryver, Nicolas, additional, de Mey, Nathalie, additional, Layios, Nathalie, additional, Mesland, Jean-Baptiste, additional, Robinet, Sébastien, additional, Cavalier, Etienne, additional, Donneau, Anne-Françoise, additional, Moutschen, Michel, additional, and Laterre, Pierre-François, additional

Published
2024
Full Text
View/download PDF

3. Convalescent Plasma for Covid-19–Induced ARDS in Mechanically Ventilated Patients

Author

Misset, Benoît, primary, Piagnerelli, Michael, additional, Hoste, Eric, additional, Dardenne, Nadia, additional, Grimaldi, David, additional, Michaux, Isabelle, additional, De Waele, Elisabeth, additional, Dumoulin, Alexander, additional, Jorens, Philippe G., additional, van der Hauwaert, Emmanuel, additional, Vallot, Frédéric, additional, Lamote, Stoffel, additional, Swinnen, Walter, additional, De Schryver, Nicolas, additional, Fraipont, Vincent, additional, de Mey, Nathalie, additional, Dauby, Nicolas, additional, Layios, Nathalie, additional, Mesland, Jean-Baptiste, additional, Meyfroidt, Geert, additional, Moutschen, Michel, additional, Compernolle, Veerle, additional, Gothot, André, additional, Desmecht, Daniel, additional, Taveira da Silva Pereira, Maria I., additional, Garigliany, Mutien, additional, Najdovski, Tome, additional, Bertrand, Axelle, additional, Donneau, Anne-Françoise, additional, and Laterre, Pierre-François, additional

Published
2023
Full Text
View/download PDF

4. Convalescent Plasma for Covid-19–Induced ARDS in Mechanically Ventilated Patients

Author

Misset, Benoit, Piagnerelli, Michaël, Hoste, Eric, Dardenne, Nadia, Grimaldi, David, Michaux, Isabelle, De Waele, Elisabeth, Dumoulin, Alexander, Jorens, Philippe G, van der Hauwaert, Emmanuel, Vallot, Frédéric, Lamote, Stoffel, Swinnen, Walter, De Schryver, Nicolas, Fraipont, Vincent, de Mey, Nathalie, Dauby, Nicolas, Layios, Nathalie, Mesland, Jean Baptiste, Meyfroidt, Geert, Moutschen, Michel, Compernolle, Veerle, Gothot, André, Desmecht, Daniel, Taveira da Silva Pereira, Maria, Garigliany, Mutien, Najdovski, Tome, Bertrand, Axelle, Donneau, Anne-Françoise, Laterre, Pierre-Francois, Misset, Benoit, Piagnerelli, Michaël, Hoste, Eric, Dardenne, Nadia, Grimaldi, David, Michaux, Isabelle, De Waele, Elisabeth, Dumoulin, Alexander, Jorens, Philippe G, van der Hauwaert, Emmanuel, Vallot, Frédéric, Lamote, Stoffel, Swinnen, Walter, De Schryver, Nicolas, Fraipont, Vincent, de Mey, Nathalie, Dauby, Nicolas, Layios, Nathalie, Mesland, Jean Baptiste, Meyfroidt, Geert, Moutschen, Michel, Compernolle, Veerle, Gothot, André, Desmecht, Daniel, Taveira da Silva Pereira, Maria, Garigliany, Mutien, Najdovski, Tome, Bertrand, Axelle, Donneau, Anne-Françoise, and Laterre, Pierre-Francois

Abstract

Background Passive immunization with plasma collected from convalescent patients has been regularly used to treat coronavirus disease 2019 (Covid-19). Minimal data are available regarding the use of convalescent plasma in patients with Covid-19-induced acute respiratory distress syndrome (ARDS). Methods In this open-label trial, we randomly assigned adult patients with Covid-19-induced ARDS who had been receiving invasive mechanical ventilation for less than 5 days in a 1:1 ratio to receive either convalescent plasma with a neutralizing antibody titer of at least 1:320 or standard care alone. Randomization was stratified according to the time from tracheal intubation to inclusion. The primary outcome was death by day 28. Results A total of 475 patients underwent randomization from September 2020 through March 2022. Overall, 237 patients were assigned to receive convalescent plasma and 238 to receive standard care. Owing to a shortage of convalescent plasma, a neutralizing antibody titer of 1:160 was administered to 17.7% of the patients in the convalescent-plasma group. Glucocorticoids were administered to 466 patients (98.1%). At day 28, mortality was 35.4% in the convalescent-plasma group and 45.0% in the standard-care group (P=0.03). In a prespecified analysis, this effect was observed mainly in patients who underwent randomization 48 hours or less after the initiation of invasive mechanical ventilation. Serious adverse events did not differ substantially between the two groups. Conclusions The administration of plasma collected from convalescent donors with a neutralizing antibody titer of at least 1:160 to patients with Covid-19-induced ARDS within 5 days after the initiation of invasive mechanical ventilation significantly reduced mortality at day 28. This effect was mainly observed in patients who underwent randomization 48 hours or less after ventilation initiation. (Funded by the Belgian Health Care Knowledge Center; ClinicalTrials.gov number, NCT0, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2023

6. Early Prediction of High-Flow Oxygen Therapy Failure in COVID-19 Acute Hypoxemic Respiratory Failure: A Retrospective Study of Scores and Thresholds.

Author

UCL - (SLuc) Service de gériatrie, Talpos, Mircea T, Rasson, Anaximandre, de Terwangne, Christophe, Simonet, Olivier, Taccone, Fabio S, Vallot, Frédéric, UCL - (SLuc) Service de gériatrie, Talpos, Mircea T, Rasson, Anaximandre, de Terwangne, Christophe, Simonet, Olivier, Taccone, Fabio S, and Vallot, Frédéric

Abstract

Background High-flow oxygen therapy (HFOT) has been widely used as an effective alternative to invasive mechanical ventilation (IMV) in some critically ill patients with COVID-19 pneumonia. This study aimed to compare different tools, including the respiratory rate and oxygenation (ROX) index, to predict HFOT failure in this setting. Methodology This single-center retrospective observational study was conducted from September to December 2020 and assessed COVID-19 patients who required HFOT as the first treatment at admission; HFOT failure was defined as IMV use. Prognostic scoring tools were as follows: the Sequential Organ Failure Assessment (SOFA), Acute Physiology And Chronic Health Evaluation (APACHE) II, and Simplified Acute Physiology Score (SAPS) III scores; C-reactive protein; lung consolidation percentage on chest CT; mean partial pressure of oxygen in arterial blood (PaO)/fraction of inspired oxygen (FiO) ratio; and ROX index and modified ROX index, calculated using PaO instead of blood oxygen saturation, within the first 24 hours after admission to the intensive care unit (ICU). These scores were analyzed using a multivariate Cox proportional hazard model; optimal cutoffs were computed using the R system for statistical computing. Results The study enrolled 52 patients, 31 (60%) of whom experienced HFOT failure. The best predictors of HFOT failure measured 24 hours after HFOT initiation were as follows: PaO/FiO (threshold 123.6, sensitivity 87%, specificity 81%, hazard ratio [HR] 7.76, and 95% confidence interval [CI] 2.39-17.1); ROX index (threshold 5.63, sensitivity 68%, specificity 95%, HR 6.18, and 95% CI 2.54-13.4); and modified ROX index (threshold 4.94, sensitivity 81%, specificity 90%, HR 8.16, and 95% CI 3.16-21.5) ( < 0.001 for all). Conclusions Early assessment of the ROX index, modified ROX index, and PaO/FiO ratio can adequately predict, with high accuracy, HFOT failure in COVID-19 patients. Because thresholds remain debated and are still no

Published
2022

7. Reduced anticoagulation targets in extracorporeal life support (RATE): study protocol for a randomized controlled trial

Author

van Minnen, Olivier, Oude Lansink-Hartgring, Annemieke, van den Boogaard, Bas, van den Brule, Judith Maria Dimphena, Bulpa, Pierre, Bunge, Jeroen J.J.H., Delnoij, Thijs, Elzo Kraemer, Carlos C.V., Kuijpers, Marijn, Lambermont, Bernard, Maas, Jacinta J.J., de Metz, Jesse, Michaux, Isabelle, van de Pol, Ineke, van de Poll, Marcel M.C.G., Raasveld, Senta Jorinde, Raes, Matthias, Dos Reis Miranda, Dinis, Scholten, Erik, Simonet, Olivier, Taccone, Fabio, Vallot, Frédéric, Vlaar, Alexander Petrus Johannes, van den Bergh, Walter Marcel, van Minnen, Olivier, Oude Lansink-Hartgring, Annemieke, van den Boogaard, Bas, van den Brule, Judith Maria Dimphena, Bulpa, Pierre, Bunge, Jeroen J.J.H., Delnoij, Thijs, Elzo Kraemer, Carlos C.V., Kuijpers, Marijn, Lambermont, Bernard, Maas, Jacinta J.J., de Metz, Jesse, Michaux, Isabelle, van de Pol, Ineke, van de Poll, Marcel M.C.G., Raasveld, Senta Jorinde, Raes, Matthias, Dos Reis Miranda, Dinis, Scholten, Erik, Simonet, Olivier, Taccone, Fabio, Vallot, Frédéric, Vlaar, Alexander Petrus Johannes, and van den Bergh, Walter Marcel

Abstract

Background: Although life-saving in selected patients, ECMO treatment still has high mortality which for a large part is due to treatment-related complications. A feared complication is ischemic stroke for which heparin is routinely administered for which the dosage is usually guided by activated partial thromboplastin time (aPTT). However, there is no relation between aPTT and the rare occurrence of ischemic stroke (1.2%), but there is a relation with the much more frequent occurrence of bleeding complications (55%) and blood transfusion. Both are strongly related to outcome. Methods: We will conduct a three-arm non-inferiority randomized controlled trial, in adult patients treated with ECMO. Participants will be randomized between heparin administration with a target of 2–2.5 times baseline aPTT, 1.5–2 times baseline aPTT, or low molecular weight heparin guided by weight and renal function. Apart from anticoagulation targets, treatment will be according to standard care. The primary outcome parameter is a combined endpoint consisting of major bleeding including hemorrhagic stroke, severe thromboembolic complications including ischemic stroke, and mortality at 6 months. Discussion: We hypothesize that with lower anticoagulation targets or anticoagulation with LMWH during ECMO therapy, patients will have fewer hemorrhagic complications without an increase in thromboembolic complication or a negative effect on their outcome. If our hypothesis is confirmed, this study could lead to a change in anticoagulation protocols and a better outcome for patients treated with ECMO. Trial registration: ClinicalTrials.gov NCT04536272. Registered on 2 September 2020. Netherlands Trial Register NL7969, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2022

10. Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis

Author

Vallot Frédéric, Mascaux Céline, Martin Benoît, Berghmans Thierry, Paesmans Marianne, Meert Anne-Pascale, Verdebout Jean-Marc, Lafitte Jean-Jacques, and Sculier Jean-Paul

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Purpose A systematic review of the literature was carried out to determine the role of prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC) . Methods To be eligible, full published trials needed to deal with SCLC and to have randomly assigned patients to receive PCI or not. Trials quality was assessed by two scores (Chalmers and ELCWP). Results Twelve randomised trials (1547 patients) were found to be eligible. Five evaluated the role of PCI in SCLC patients who had complete response (CR) after chemotherapy. Brain CT scan was done in the work-up in five studies and brain scintigraphy in six. Chalmers and ELCWP scores are well correlated (p < 0.001), with respective median scores of 32.6 and 38.8 %. This meta-analysis based on the available published data reveals a decrease of brain metastases incidence (hazard ratio (HR): 0.48; 95 % confidence interval (CI): 0.39 - 0.60) for all the studies and an improvement of survival (HR: 0.82; 95 % CI: 0.71 - 0.96) in patients in CR in favour of the PCI arm. Unfortunately, long-term neurotoxicity was not adequately described . Conclusions PCI decreases brain metastases incidence and improves survival in CR SCLC patients but these effects were obtained in patients who had no systematic neuropsychological and brain imagery assessments. The long-term toxicity has not been prospectively evaluated. If PCI can be recommended in patients with SCLC and CR documented by a work-up including brain CT scan, data are lacking to generalise its use to any CR situations.

Published
2001
Full Text
View/download PDF

11. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis.

Author

Martin, Benoît, Paesmans, Marianne, Berghmans, Thierry, Branle, Fabrice, Ghisdal, Lidia, Mascaux, Céline, Meert, Anne-Pascale, Steels, Emmanuelle, Vallot, Frédéric, Verdebout, Jean-Marc, Lafitte, Jean-Jacques, Sculier, Jean-Paul, Martin, Benoît, Paesmans, Marianne, Berghmans, Thierry, Branle, Fabrice, Ghisdal, Lidia, Mascaux, Céline, Meert, Anne-Pascale, Steels, Emmanuelle, Vallot, Frédéric, Verdebout, Jean-Marc, Lafitte, Jean-Jacques, and Sculier, Jean-Paul

Abstract

The role of the anti-apoptotic protein Bcl-2 in lung cancer remains controversial. In order to clarify its impact on survival in small and non-small cell lung cancer (NSCLC), we performed a systematic review of the literature. Trials were selected for further analysis if they provided an independent assessment of Bcl-2 in lung cancer and reported analysis of survival data according to Bcl-2 status. To make it possible to aggregate survival results of the published studies, their methodology was assessed using a quality scale designed by the European Lung Cancer Working Party (including study design, laboratory methods and analysis). Of 28 studies, 11 identified Bcl-2 expression as a favourable prognostic factor and three linked it with poor prognosis; 14 trials were not significant. No differences in scoring measurement were detected between the studies, except that significantly higher scores were found in the trials with the largest sample sizes. Assessments of methodology and of laboratory technique were made independently of the conclusion of the trials. A total of 25 trials, comprising 3370 patients, provided sufficient information for the meta-analysis. The studies were categorised according to histology, disease stage and laboratory technique. The combined hazard ratio (HR) suggested that a positive Bcl-2 status has a favourable impact on survival: 0.70 (95% confidence interval 0.57-0.86) in seven studies on stages I-II NSCLC; 0.50 (0.39-0.65) in eight studies on surgically resected NSCLC; 0.91 (0.76-1.10) in six studies on any stage NSCLC; 0.57 (0.41-0.78) in five studies on squamous cell cancer; 0.75 (0.61-0.93) and 0.71 (0.61-0.83) respectively for five studies detecting Bcl-2 by immunohistochemistry with Ab clone 100 and for 13 studies assessing Bcl-2 with Ab clone 124; 0.92 (0.73-1.16) for four studies on small cell lung cancer; 1.26 (0.58-2.72) for three studies on neuroendocrine tumours. In NSCLC, Bcl-2 expression was associated with a better prognosis, Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review, info:eu-repo/semantics/published

Published
2003

14. Prophylactic cerebral irradiation in small cell lung cancer: a systematic review of the literature with meta-analyses

Author

Second World Conference on Clinical Cooperative Research for Lung Cancer (March 2002: Brussels, Belgium), Meert, Anne-Pascale, Paesmans, Marianne, Berghmans, Thierry, Martin, Benoît, Mascaux, Céline, Vallot, Frédéric, Verdebout, Jean-Marc, Lafitte, Jean-Jacques, Sculier, Jean-Paul, Second World Conference on Clinical Cooperative Research for Lung Cancer (March 2002: Brussels, Belgium), Meert, Anne-Pascale, Paesmans, Marianne, Berghmans, Thierry, Martin, Benoît, Mascaux, Céline, Vallot, Frédéric, Verdebout, Jean-Marc, Lafitte, Jean-Jacques, and Sculier, Jean-Paul

Abstract

info:eu-repo/semantics/nonPublished

Published
2002

15. La leucopénie est un facteur pronostique péjoratif chez le patient atteint d’un cancer avec une complication nécessitant une ventilation mécanique invasive

Author

Meert, Anne-Pascale, Vallot, Frédéric, Paesmans, Marianne, Berghmans, Thierry, Sculier, Jean-Paul, Meert, Anne-Pascale, Vallot, Frédéric, Paesmans, Marianne, Berghmans, Thierry, and Sculier, Jean-Paul

Abstract

SRLF Janvier 2003. Réanimation 2002 Décembre; 11 (S3): 97 (SP28)., info:eu-repo/semantics/published

Published
2002

16. Prophylactic cranial irradiation in SCLC: a systematic review of the literature with meta-analysis

Author

Meert, Anne-Pascale, Paesmans, Marianne, Berghmans, Thierry, Martin, Bénédicte, Mascaux, Céline, Vallot, Frédéric, Verdebout, Jean-Marc, Lafitte, Jean-Jacques, Sculier, Jean-Paul, Meert, Anne-Pascale, Paesmans, Marianne, Berghmans, Thierry, Martin, Bénédicte, Mascaux, Céline, Vallot, Frédéric, Verdebout, Jean-Marc, Lafitte, Jean-Jacques, and Sculier, Jean-Paul

Abstract

info:eu-repo/semantics/published

Published
2002

17. Haematological colony-stimulating factors (CSF) in febrile neutropenic patients: a systematic review of the literature with meta-analysis.

Author

Paesmans, Marianne, Berghmans, Thierry, Lafitte, Jean-Jacques, Vallot, Frédéric, Meert, Anne-Pascale, Steels, Emmanuelle, Mascaux, Céline, Sculier, Jean-Paul, Paesmans, Marianne, Berghmans, Thierry, Lafitte, Jean-Jacques, Vallot, Frédéric, Meert, Anne-Pascale, Steels, Emmanuelle, Mascaux, Céline, and Sculier, Jean-Paul

Abstract

14th MASCC International Symposium, Boston, USA, 2002, info:eu-repo/semantics/published

Published
2002

18. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients: A systematic review of the literature with meta-analysis

Author

Berghmans, Thierry, Paesmans, Marianne, Lafitte, Jean-Jacques, Mascaux, Céline, Meert, Anne-Pascale, Jacquy, Caroline, Burniat, Agnès, Steels, Emmanuelle, Vallot, Frédéric, Sculier, Jean-Paul, Berghmans, Thierry, Paesmans, Marianne, Lafitte, Jean-Jacques, Mascaux, Céline, Meert, Anne-Pascale, Jacquy, Caroline, Burniat, Agnès, Steels, Emmanuelle, Vallot, Frédéric, and Sculier, Jean-Paul

Abstract

SCOPUS: re.j, info:eu-repo/semantics/published

Published
2002

19. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis.

Author

Steels, Emmanuelle, Paesmans, Marianne, Berghmans, Thierry, Branle, Fabrice, Lemaitre, France, Mascaux, Céline, Meert, Anne-Pascale, Vallot, Frédéric, Lafitte, Jean-Jacques, Sculier, Jean-Paul, Steels, Emmanuelle, Paesmans, Marianne, Berghmans, Thierry, Branle, Fabrice, Lemaitre, France, Mascaux, Céline, Meert, Anne-Pascale, Vallot, Frédéric, Lafitte, Jean-Jacques, and Sculier, Jean-Paul

Abstract

The role of p53, as a prognostic factor for survival in lung cancer, is controversial and the purpose of the present systematic review of the literature is to determine this effect. Published studies were identified with the objective to aggregate the available survival results after a methodological assessment using a scale specifically designed by the European Lung Cancer Working Party (ELCWP). To be eligible, a study had to deal with p53 assessment in lung cancer (primary site) only, and to provide a survival comparison according to the p53 status. Among the 74 eligible papers, 30 identified p53 abnormalities as a univariate statistically significant poor prognostic factor and 56 provided sufficient data to allow survival results aggregation. There was no significant difference between the trials that either showed or did not show a prognostic effect of p53 according to the methodological score or to the laboratory technique used. The studies were categorized by histology, disease stage, treatment and laboratory technique. Combined hazard ratios suggested that an abnormal p53 status had an unfavourable impact on survival: in any stage nonsmall cell lung cancer (NSCLC) the mean (95% confidence interval) was 1.44 (1.20-1.72) (number of studies included in the subgroup was 11), 1.50 (1.32-1.70) in stages I-II NSCLC (n=19), 1.68 (1.23-2.29) in stages I-IIIB NSCLC (n=5), 1.68 (1.30-2.18) in stages III-IV NSCLC (n=9), 1.48 (1.29-1.70) in surgically resected NSCLC (n=20), 1.37 (1.02-1.85) in squamous cell carcinoma (n=9), 2.24 (1.70-2.95) in adenocarcinoma (n=9), 1.57 (1.28-1.91) for a positive immunohistochemistry with antibody 1801 (n=8), 1.25 (1.09-1.43) for a positive immunohistochemistry with antibody DO-7 (n=16), and 1.65 (1.35-2.00) for an abnormal molecular biology test (n=13). Data were insufficient to determine the prognostic value of p53 in small cell lung cancer. In each subgroup of nonsmall cell lung cancer, p53 abnormal status was shown to be associated wi, Journal Article, Meta-Analysis, info:eu-repo/semantics/published

Published
2001

20. Haematological colony-stimulating factors (CSF) in febrile neutropenic patients: A systematic review of the literature with meta-analysis

Author

Berghmans, Thierry, Paesmans, Marianne, Lafitte, Jean-Jacques, Meert, Anne-Pascale, Mascaux, Céline, Steels, Emmanuelle, Vallot, Frédéric, Sculier, Jean-Paul, Berghmans, Thierry, Paesmans, Marianne, Lafitte, Jean-Jacques, Meert, Anne-Pascale, Mascaux, Céline, Steels, Emmanuelle, Vallot, Frédéric, and Sculier, Jean-Paul

Abstract

6, info:eu-repo/semantics/published

Published
2001

21. Is there a need for prophylactic cranial irradiation in small-cell lung cancer? No: Current topics

Author

Meert, Anne-Pascale, Paesmans, Marianne, Berghmans, Thierry, Martin, Benoît, Mascaux, Céline, Vallot, Frédéric, Verdebout, Jean-Marc, Lafitte, Jean-Jacques, Sculier, Jean-Paul, Meert, Anne-Pascale, Paesmans, Marianne, Berghmans, Thierry, Martin, Benoît, Mascaux, Céline, Vallot, Frédéric, Verdebout, Jean-Marc, Lafitte, Jean-Jacques, and Sculier, Jean-Paul

Abstract

info:eu-repo/semantics/published

Published
2001

22. Is there a need for prophylactic cranial irradiation in small cell lung cancer ?No.

Author

Sculier, Jean-Paul, Meert, Anne-Pascale, Paesmans, Marianne, Berghmans, Thierry, Martin, Benoît, Mascaux, Céline, Vallot, Frédéric, Verdebout, Jean-Marc, Lafitte, Jean-Jacques, Sculier, Jean-Paul, Meert, Anne-Pascale, Paesmans, Marianne, Berghmans, Thierry, Martin, Benoît, Mascaux, Céline, Vallot, Frédéric, Verdebout, Jean-Marc, and Lafitte, Jean-Jacques

Abstract

7th Central European Lung Cancer Conference, Prague, Czech Republic, 2001, info:eu-repo/semantics/published

Published
2001

23. Rôle de la positivité de Bcl-2 sur la survie des patients atteints d'un cancer pulmonaire: revue systématique de la littérature et méta-analyse.

Author

Martin, Benoît, Paesmans, Marianne, Berghmans, Thierry, Branle, Fabrice, Burniat, Agnès, Ghisdal, Lidia, Mascaux, Céline, Meert, Anne-Pascale, Steels, Emmanuelle, Vallot, Frédéric, Verdebout, Jean-Marc, Lafitte, Jean-Jacques, Sculier, Jean-Paul, Martin, Benoît, Paesmans, Marianne, Berghmans, Thierry, Branle, Fabrice, Burniat, Agnès, Ghisdal, Lidia, Mascaux, Céline, Meert, Anne-Pascale, Steels, Emmanuelle, Vallot, Frédéric, Verdebout, Jean-Marc, Lafitte, Jean-Jacques, and Sculier, Jean-Paul

Abstract

5eme Congrès de Pneumologie de Langue Française, Paris, France, 2001, info:eu-repo/semantics/published

Published
2001

24. Rôle de la positivité de p53 sur la survie des patients atteints d'un cancer pulmonaire: revue systématique de la littérature avec méta-analyse.

Author

Meert, Anne-Pascale, Steels, Emmanuelle, Paesmans, Marianne, Berghmans, Thierry, Branle, Fabrice, Burniat, Agnès, Ghisdal, Lidia, Lemaitre, France, Martin, Benoît, Mascaux, Céline, Vallot, Frédéric, Lafitte, Jean-Jacques, Sculier, Jean-Paul, Meert, Anne-Pascale, Steels, Emmanuelle, Paesmans, Marianne, Berghmans, Thierry, Branle, Fabrice, Burniat, Agnès, Ghisdal, Lidia, Lemaitre, France, Martin, Benoît, Mascaux, Céline, Vallot, Frédéric, Lafitte, Jean-Jacques, and Sculier, Jean-Paul

Abstract

5eme Congrès de Pneumologie de Langue Française, Paris, France, 2001, info:eu-repo/semantics/published

Published
2001

26. La place de la chimiothérapie dans le traitement des cancers bronchiques non à petites cellules, non métastatiques

Author

Sculier, Jean-Paul, Berghmans, Thierry, Paesmans, Marianne, Branle, Fabrice, Lemaitre, France, Mascaux, Céline, Meert, Anne-Pascale, Steels, Emmanuelle, Vallot, Frédéric, Lafitte, Jean-Jacques, Sculier, Jean-Paul, Berghmans, Thierry, Paesmans, Marianne, Branle, Fabrice, Lemaitre, France, Mascaux, Céline, Meert, Anne-Pascale, Steels, Emmanuelle, Vallot, Frédéric, and Lafitte, Jean-Jacques

Abstract

SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2001

28. Mitomycin C (MMC) in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis with qualitative assessment.

Author

Berghmans, Thierry, Ghisdal, Lidia, Paesmans, Marianne, Branle, Fabrice, Lafitte, Jean-Jacques, Vallot, Frédéric, Meert, Anne-Pascale, Lemaitre, France, Steels, Emmanuelle, Burniat, Agnès, Mascaux, Céline, Sculier, Jean-Paul, Berghmans, Thierry, Ghisdal, Lidia, Paesmans, Marianne, Branle, Fabrice, Lafitte, Jean-Jacques, Vallot, Frédéric, Meert, Anne-Pascale, Lemaitre, France, Steels, Emmanuelle, Burniat, Agnès, Mascaux, Céline, and Sculier, Jean-Paul

Abstract

European Respiratory Society Annual Meeting, Florence, Italy, Abstract P2367, info:eu-repo/semantics/published

Published
2000

29. Role of p53 positivity on the survival of patients with lung cancer as assessed by a systematic review of the literature.

Author

Steels, Emmanuelle, Paesmans, Marianne, Berghmans, Thierry, Branle, Fabrice, Burniat, Agnès, Ghisdal, Lidia, Lafitte, Jean-Jacques, Lemaitre, France, Mascaux, Céline, Meert, Anne-Pascale, Vallot, Frédéric, Sculier, Jean-Paul, Steels, Emmanuelle, Paesmans, Marianne, Berghmans, Thierry, Branle, Fabrice, Burniat, Agnès, Ghisdal, Lidia, Lafitte, Jean-Jacques, Lemaitre, France, Mascaux, Céline, Meert, Anne-Pascale, Vallot, Frédéric, and Sculier, Jean-Paul

Abstract

10th European Respiratory Society Annual Meeting, Florence, Italy, 30/08-03/09/2000, Abstract P2598, info:eu-repo/semantics/published

Published
2000

30. Survie et sevrage de la ventilation mécanique d'une population de patients cancéreux

Author

Vallot, Frédéric, Berghmans, Thierry, Markiewicz, Eveline, Sculier, Jean-Paul, Vallot, Frédéric, Berghmans, Thierry, Markiewicz, Eveline, and Sculier, Jean-Paul

Abstract

XXVIIIe Congrès de la société de réanimation de Langue Française, CNIT, Paris-la-Défense, 19-20/01/2000, info:eu-repo/semantics/published, suppl3: SP111

Published
2000

31. Treatment with or without chemotherapy for locally advanced non small cell lung cancer (NSCLC): a systematic review by the European Lung Cancer Working Party

Author

Paesmans, Marianne, Berghmans, Thierry, Vallot, Frédéric, Branle, Fabrice, Lafitte, Jean-Jacques, Lemaitre, France, Mascaux, Céline, Meert, Anne-Pascale, Steels, Emmanuelle, Paesmans, Marianne, Berghmans, Thierry, Vallot, Frédéric, Branle, Fabrice, Lafitte, Jean-Jacques, Lemaitre, France, Mascaux, Céline, Meert, Anne-Pascale, and Steels, Emmanuelle

Abstract

9th World Conference on Lung Cancer, 11-15/09/2000 (Japan), info:eu-repo/semantics/published, suppl 2: 293

Published
2000

32. The role of mitomycin C (MMC) in the treatment of non-small cell lung cancer (NSCLC):a meta-analysis of the literature

Author

Berghmans, Thierry, Ghisdal, Lidia, Paesmans, Marianne, Branle, Fabrice, Lafitte, Jean-Jacques, Vallot, Frédéric, Meert, Anne-Pascale, Lemaitre, France, Steels, Emmanuelle, Burniat, Agnès, Mascaux, Céline, Sculier, Jean-Paul, Berghmans, Thierry, Ghisdal, Lidia, Paesmans, Marianne, Branle, Fabrice, Lafitte, Jean-Jacques, Vallot, Frédéric, Meert, Anne-Pascale, Lemaitre, France, Steels, Emmanuelle, Burniat, Agnès, Mascaux, Céline, and Sculier, Jean-Paul

Abstract

498 (*1949), info:eu-repo/semantics/published

Published
2000

33. It is a place for mitomycin (MMC) in the treatment of non-small cell lung cancer (NSCLC) ?a meta-analysis.

Author

Berghmans, Thierry, Ghisdal, Lidia, Paesmans, Marianne, Branle, Fabrice, Burniat, Agnès, Lafitte, Jean-Jacques, Lemaitre, France, Mascaux, Céline, Meert, Anne-Pascale, Steels, Emmanuelle, Vallot, Frédéric, Sculier, Jean-Paul, Berghmans, Thierry, Ghisdal, Lidia, Paesmans, Marianne, Branle, Fabrice, Burniat, Agnès, Lafitte, Jean-Jacques, Lemaitre, France, Mascaux, Céline, Meert, Anne-Pascale, Steels, Emmanuelle, Vallot, Frédéric, and Sculier, Jean-Paul

Abstract

9th World Conference on Lung Cancer, Tokyo, Japan, 2000, abstract 175A, info:eu-repo/semantics/published

Published
2000

34. p53 est-il un facteur pronostique pour la survie dans le cancer bronchique ?

Author

Journée Annuelle d'Oncologie Thoracique (2000: Bruxelles), Paesmans, Marianne, Steels, Emmanuelle, Berghmans, Thierry, Meert, Anne-Pascale, Vallot, Frédéric, Lemaitre, France, Branle, Fabrice, Mascaux, Céline, Lafitte, Jean-Jacques, Sculier, Jean-Paul, Journée Annuelle d'Oncologie Thoracique (2000: Bruxelles), Paesmans, Marianne, Steels, Emmanuelle, Berghmans, Thierry, Meert, Anne-Pascale, Vallot, Frédéric, Lemaitre, France, Branle, Fabrice, Mascaux, Céline, Lafitte, Jean-Jacques, and Sculier, Jean-Paul

Abstract

info:eu-repo/semantics/nonPublished

Published
2000

35. Role of p53 positivity on the survival of patients with lung cancer as assessed by a systematic review of the literature.

Author

Paesmans, Marianne, Steels, Emmanuelle, Berghmans, Thierry, Branle, Fabrice, Burniat, Agnès, Ghisdal, Lidia, Lafitte, Jean-Jacques, Lemaitre, France, Mascaux, Céline, Meert, Anne-Pascale, Vallot, Frédéric, Sculier, Jean-Paul, Paesmans, Marianne, Steels, Emmanuelle, Berghmans, Thierry, Branle, Fabrice, Burniat, Agnès, Ghisdal, Lidia, Lafitte, Jean-Jacques, Lemaitre, France, Mascaux, Céline, Meert, Anne-Pascale, Vallot, Frédéric, and Sculier, Jean-Paul

Abstract

9th World Conference on Lung Cancer, Tokyo, Japan, 11-15/09/2000, abstract 620, info:eu-repo/semantics/published

Published
2000

36. Treatment with or without chemotherapy for locally advanced non-small cell lung cancer (NSCLC): a systematic review.

Author

Paesmans, Marianne, Berghmans, Thierry, Vallot, Frédéric, Branle, Fabrice, Lafitte, Jean-Jacques, Lemaitre, France, Mascaux, Céline, Meert, Anne-Pascale, Steels, Emmanuelle, Sculier, Jean-Paul, Paesmans, Marianne, Berghmans, Thierry, Vallot, Frédéric, Branle, Fabrice, Lafitte, Jean-Jacques, Lemaitre, France, Mascaux, Céline, Meert, Anne-Pascale, Steels, Emmanuelle, and Sculier, Jean-Paul

Abstract

9th World Conference on Lung Cancer, Tokyo, Japan, 2000, Abstract 293, info:eu-repo/semantics/published

Published
2000

37. Role of p53 positivity on the survival of patients with lung cancer as assessed by a systematic review of the literature.

Author

Berghmans, Thierry, Steels, Emmanuelle, Paesmans, Marianne, Branle, Fabrice, Burniat, Agnès, Ghisdal, Lidia, Lafitte, Jean-Jacques, Lemaitre, France, Mascaux, Céline, Meert, Anne-Pascale, Vallot, Frédéric, Sculier, Jean-Paul, Berghmans, Thierry, Steels, Emmanuelle, Paesmans, Marianne, Branle, Fabrice, Burniat, Agnès, Ghisdal, Lidia, Lafitte, Jean-Jacques, Lemaitre, France, Mascaux, Céline, Meert, Anne-Pascale, Vallot, Frédéric, and Sculier, Jean-Paul

Abstract

5th International Symposium on Predictive Oncology and Therapy, Geneva, Switzerland, 2000, info:eu-repo/semantics/published

Published
2000

38. Role of bcl-2 positivity on survival in patients with lung cancer: a meta-analysis with qualitative assessment of the literature

Author

Berghmans, Thierry, Martin, Benoît, Paesmans, Marianne, Branle, Fabrice, Burniat, Agnès, Ghisdal, Lidia, Mascaux, Céline, Meert, Anne-Pascale, Steels, Emmanuelle, Vallot, Frédéric, Verdebout, Jean-Marc, Lafitte, Jean-Jacques, Sculier, Jean-Paul, Berghmans, Thierry, Martin, Benoît, Paesmans, Marianne, Branle, Fabrice, Burniat, Agnès, Ghisdal, Lidia, Mascaux, Céline, Meert, Anne-Pascale, Steels, Emmanuelle, Vallot, Frédéric, Verdebout, Jean-Marc, Lafitte, Jean-Jacques, and Sculier, Jean-Paul

Abstract

5th International Symposium on Predictive Oncology and Therapy, Geneva, Switzerland, 2000, info:eu-repo/semantics/published

Published
2000

39. Chemoradiotherapy for stage III unresectable non small cell lung cancer (NSCLC): a systematic review by the European Lung Cancer Working Party (ELCWP).

Author

Paesmans, Marianne, Berghmans, Thierry, Vallot, Frédéric, Branle, Fabrice, Lafitte, Jean-Jacques, Lemaitre, France, Mascaux, Céline, Meert, Anne-Pascale, Steels, Emmanuelle, Sculier, Jean-Paul, Paesmans, Marianne, Berghmans, Thierry, Vallot, Frédéric, Branle, Fabrice, Lafitte, Jean-Jacques, Lemaitre, France, Mascaux, Céline, Meert, Anne-Pascale, Steels, Emmanuelle, and Sculier, Jean-Paul

Abstract

ERS Annual Congress, Madrid, Spain, Abstract P2912, info:eu-repo/semantics/published

Published
1999

40. Corticosteroids in sepsis and septic shock. A Meta-analysis

Author

Lemaitre, France, Berghmans, Thierry, Branle, Fabrice, Gordower, Laurence, Mascaux, Céline, Meert, Anne-Pascale, Paesmans, Marianne, Slama, A., Steels, Emmanuelle, Vallot, Frédéric, Sculier, Jean-Paul, Lemaitre, France, Berghmans, Thierry, Branle, Fabrice, Gordower, Laurence, Mascaux, Céline, Meert, Anne-Pascale, Paesmans, Marianne, Slama, A., Steels, Emmanuelle, Vallot, Frédéric, and Sculier, Jean-Paul

Abstract

info:eu-repo/semantics/published

Published
1999

42. Chemoradiotherapy for advanced non-small cell lung carcinoma (NSCLC) qualitative and quantitative evaluation of the literature.

Author

Berghmans, Thierry, Vallot, Frédéric, Branle, Fabrice, Lafitte, Jean-Jacques, Lemaitre, France, Mascaux, Céline, Meert, Anne-Pascale, Paesmans, Marianne, Steels, Emmanuelle, Sculier, Jean-Paul, Berghmans, Thierry, Vallot, Frédéric, Branle, Fabrice, Lafitte, Jean-Jacques, Lemaitre, France, Mascaux, Céline, Meert, Anne-Pascale, Paesmans, Marianne, Steels, Emmanuelle, and Sculier, Jean-Paul

Abstract

ECCO 10, Vienna, Austria, Abstract 1007a, info:eu-repo/semantics/published

Published
1999

43. Corticosteroids in sepsis and septic shock: a meta-analysis.

Author

Société Belge de Médecine Intensive et de Médecine d'Urgence, Spring Meeting (1999: Ghent, Belgium), Lemaitre, France, Berghmans, Thierry, Branle, Fabrice, Gordower, Laurence, Mascaux, Céline, Meert, Anne-Pascale, Paesmans, Marianne, Slama, A., Steels, Emmanuelle, Vallot, Frédéric, Sculier, Jean-Paul, Société Belge de Médecine Intensive et de Médecine d'Urgence, Spring Meeting (1999: Ghent, Belgium), Lemaitre, France, Berghmans, Thierry, Branle, Fabrice, Gordower, Laurence, Mascaux, Céline, Meert, Anne-Pascale, Paesmans, Marianne, Slama, A., Steels, Emmanuelle, Vallot, Frédéric, and Sculier, Jean-Paul

Abstract

info:eu-repo/semantics/nonPublished

Published
1999

44. Mechanical ventilation in a medical cancer patients population

Author

1st Young Intensivists Meeting SIZ (1999: Leuven), Vallot, Frédéric, Berghmans, Thierry, Markiewicz, Eveline, Sculier, Jean-Paul, 1st Young Intensivists Meeting SIZ (1999: Leuven), Vallot, Frédéric, Berghmans, Thierry, Markiewicz, Eveline, and Sculier, Jean-Paul

Abstract

info:eu-repo/semantics/nonPublished

45. Prophylactic cerebral irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis.

Author

Second World Conference on Clinical Cooperative Research for Lung Cancer (March 2002: Brussels, Belgium), Meert, Anne-Pascale, Paesmans, Marianne, Berghmans, Thierry, Martin, Benoît, Mascaux, Céline, Vallot, Frédéric, Verdebout, Jean-Marc, Lafitte, Jean-Jacques, Sculier, Jean-Paul, Second World Conference on Clinical Cooperative Research for Lung Cancer (March 2002: Brussels, Belgium), Meert, Anne-Pascale, Paesmans, Marianne, Berghmans, Thierry, Martin, Benoît, Mascaux, Céline, Vallot, Frédéric, Verdebout, Jean-Marc, Lafitte, Jean-Jacques, and Sculier, Jean-Paul

Abstract

info:eu-repo/semantics/nonPublished

46. Mechanical ventilation in a medical cancer patients population

Author

1st Young Intensivists Meeting SIZ (1999: Leuven), Vallot, Frédéric, Berghmans, Thierry, Markiewicz, Eveline, Sculier, Jean-Paul, 1st Young Intensivists Meeting SIZ (1999: Leuven), Vallot, Frédéric, Berghmans, Thierry, Markiewicz, Eveline, and Sculier, Jean-Paul

Abstract

info:eu-repo/semantics/nonPublished

47. Prophylactic cerebral irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis.

Author

Second World Conference on Clinical Cooperative Research for Lung Cancer (March 2002: Brussels, Belgium), Meert, Anne-Pascale, Paesmans, Marianne, Berghmans, Thierry, Martin, Benoît, Mascaux, Céline, Vallot, Frédéric, Verdebout, Jean-Marc, Lafitte, Jean-Jacques, Sculier, Jean-Paul, Second World Conference on Clinical Cooperative Research for Lung Cancer (March 2002: Brussels, Belgium), Meert, Anne-Pascale, Paesmans, Marianne, Berghmans, Thierry, Martin, Benoît, Mascaux, Céline, Vallot, Frédéric, Verdebout, Jean-Marc, Lafitte, Jean-Jacques, and Sculier, Jean-Paul

Abstract

info:eu-repo/semantics/nonPublished

Catalog

Books, media, physical & digital resources
See catalog results